解读国家组织药品集中采购试点:降低用药负担,规范流通秩序

2018-11-15 张泉 新华社

14日召开的中央全面深化改革委员会第五次会议审议通过了《国家组织药品集中采购试点方案》,明确了国家组织、联盟采购、平台操作的总体思路。11个试点地区委派代表组成的联合采购办公室15日发布了《4+7城市药品集中采购文件》。国家组织药品集中采购将在多大程度上减轻用药负担?对药品生产企业会产生怎样的影响?新华社记者请专家为您解读。药品“团购”,减轻群众用药负担“带量采购是本次试点的一大亮点。”上海市人

14日召开的中央全面深化改革委员会第五次会议审议通过了《国家组织药品集中采购试点方案》,明确了国家组织、联盟采购、平台操作的总体思路。11个试点地区委派代表组成的联合采购办公室15日发布了《4+7城市药品集中采购文件》。

国家组织药品集中采购将在多大程度上减轻用药负担?对药品生产企业会产生怎样的影响?新华社记者请专家为您解读

药品“团购”,减轻群众用药负担

“带量采购是本次试点的一大亮点。”上海市人社局医保处副处长龚波介绍,在此之前,药品招标采购往往只是跟药品企业确定一个中标价,并不能保证药品在本地医院的采购数量,从而使得集中采购的“团购”效应大打折扣。

在《4+7城市药品集中采购文件》中,不仅公布了31个采购品种名录,还约定每个品种的采购量。“4+7试点地区加起来大概占到全国三分之一的市场,会对药品企业产生强大的吸引力,通过企业间市场化竞价,能充分起到以量换价的作用。”龚波说。

“带量采购是国际上常见的做法,能够有效降低药品采购价格,节省医疗开支,减轻患者负担。”医改专家魏子柠表示,可以预见,此次国家组织集中采购的药品将会迎来较大幅度的降价。

多方共赢,企业亦是受益者

“医保和患者拿到比较低廉的价格,企业则拿到市场份额。”龚波表示,国家组织药品集中采购将产生多方共赢的效果,企业也将是受益者。

龚波表示,由于承诺了采购数量,企业中标后不用再担心产品销售的问题,能够节省大量促销、流通等环节的费用。

魏子柠介绍,带量采购是建立在公平竞争基础上的:企业自主决定是否参与带量采购;有正常的市场竞争秩序和规则;生产企业自主选择配送企业。在公平基础上,药品价格是与药品供应商谈判取得的双方都能够接受的结果。

“我国医药生产企业存在中小企业多、仿制药企业多、销售金额少、行业集中度低等问题,带量采购对企业加大研发投入力度、提高行业集中度、促进企业转型升级具有重要意义。”魏子柠说。

重在执行,确保带量采购正常运行

“制度设计好了,关键是执行到位。”龚波表示,国家层面组织药品集中采购,执行层面会更有力度。

“患者用药质量将得到大幅提升。”龚波表示,国家组织药品集中采购对供应商设置了较高的门槛,投标药品必须是原研药和通过国家药品监督管理局仿制药质量和疗效一致性评价的仿制药,确保治疗效果。

龚波介绍,药品集中采购之后,医保部门将与卫生部门合作,从行风建设、合理用药、临床用药综合评价等方面入手,加大对医疗机构监督,保证约定的采购量得到执行。与此同时,会出台一系列医保支持政策,及时支付带量采购货款,保障药品企业合法权益、提升其积极性。

“这样,质量、数量、货款支付,带量采购的三个要素就全部满足了。”龚波表示,强力的执行可以保证集中采购体系持续运行并取得良好效果,这是以往省级招标很难做到的。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1641658, encodeId=c6a5164165877, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Thu Jul 11 21:15:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694298, encodeId=7d75169429870, content=<a href='/topic/show?id=12a48e51263' target=_blank style='color:#2F92EE;'>#药品集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87512, encryptionId=12a48e51263, topicName=药品集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d77629597748, createdName=cathymary, createdTime=Thu Jan 17 04:15:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460099, encodeId=e0d3146009947, content=<a href='/topic/show?id=cb9d98e23ee' target=_blank style='color:#2F92EE;'>#集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98723, encryptionId=cb9d98e23ee, topicName=集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1406243727, createdName=liuxiaona, createdTime=Sat Nov 17 14:15:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532767, encodeId=6cb51532e679d, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Sat Nov 17 14:15:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352721, encodeId=ba47352e21f0, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Nov 16 00:23:43 CST 2018, time=2018-11-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1641658, encodeId=c6a5164165877, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Thu Jul 11 21:15:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694298, encodeId=7d75169429870, content=<a href='/topic/show?id=12a48e51263' target=_blank style='color:#2F92EE;'>#药品集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87512, encryptionId=12a48e51263, topicName=药品集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d77629597748, createdName=cathymary, createdTime=Thu Jan 17 04:15:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460099, encodeId=e0d3146009947, content=<a href='/topic/show?id=cb9d98e23ee' target=_blank style='color:#2F92EE;'>#集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98723, encryptionId=cb9d98e23ee, topicName=集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1406243727, createdName=liuxiaona, createdTime=Sat Nov 17 14:15:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532767, encodeId=6cb51532e679d, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Sat Nov 17 14:15:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352721, encodeId=ba47352e21f0, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Nov 16 00:23:43 CST 2018, time=2018-11-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1641658, encodeId=c6a5164165877, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Thu Jul 11 21:15:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694298, encodeId=7d75169429870, content=<a href='/topic/show?id=12a48e51263' target=_blank style='color:#2F92EE;'>#药品集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87512, encryptionId=12a48e51263, topicName=药品集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d77629597748, createdName=cathymary, createdTime=Thu Jan 17 04:15:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460099, encodeId=e0d3146009947, content=<a href='/topic/show?id=cb9d98e23ee' target=_blank style='color:#2F92EE;'>#集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98723, encryptionId=cb9d98e23ee, topicName=集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1406243727, createdName=liuxiaona, createdTime=Sat Nov 17 14:15:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532767, encodeId=6cb51532e679d, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Sat Nov 17 14:15:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352721, encodeId=ba47352e21f0, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Nov 16 00:23:43 CST 2018, time=2018-11-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1641658, encodeId=c6a5164165877, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Thu Jul 11 21:15:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694298, encodeId=7d75169429870, content=<a href='/topic/show?id=12a48e51263' target=_blank style='color:#2F92EE;'>#药品集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87512, encryptionId=12a48e51263, topicName=药品集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d77629597748, createdName=cathymary, createdTime=Thu Jan 17 04:15:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460099, encodeId=e0d3146009947, content=<a href='/topic/show?id=cb9d98e23ee' target=_blank style='color:#2F92EE;'>#集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98723, encryptionId=cb9d98e23ee, topicName=集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1406243727, createdName=liuxiaona, createdTime=Sat Nov 17 14:15:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532767, encodeId=6cb51532e679d, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Sat Nov 17 14:15:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352721, encodeId=ba47352e21f0, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Nov 16 00:23:43 CST 2018, time=2018-11-16, status=1, ipAttribution=)]
    2018-11-17 wolongzxh
  5. [GetPortalCommentsPageByObjectIdResponse(id=1641658, encodeId=c6a5164165877, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Thu Jul 11 21:15:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694298, encodeId=7d75169429870, content=<a href='/topic/show?id=12a48e51263' target=_blank style='color:#2F92EE;'>#药品集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87512, encryptionId=12a48e51263, topicName=药品集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d77629597748, createdName=cathymary, createdTime=Thu Jan 17 04:15:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460099, encodeId=e0d3146009947, content=<a href='/topic/show?id=cb9d98e23ee' target=_blank style='color:#2F92EE;'>#集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98723, encryptionId=cb9d98e23ee, topicName=集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1406243727, createdName=liuxiaona, createdTime=Sat Nov 17 14:15:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532767, encodeId=6cb51532e679d, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Sat Nov 17 14:15:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352721, encodeId=ba47352e21f0, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Nov 16 00:23:43 CST 2018, time=2018-11-16, status=1, ipAttribution=)]
    2018-11-16 飛歌

    学习了很有用不错

    0

相关资讯

14省区进口抗癌药联合议价,47个药品平均降11.3%

 记者从陕西省卫生健康委获悉,由陕西、山西、内蒙古、辽宁等14个省区组成的省际联盟日前完成进口抗癌药品联合议价工作。57个产品申报参与议价,47个产品议价成功,与14省区现行挂网价格和2017年采购量相比,平均降幅11.3%,预计每年节约资金0.91亿元。据介绍,此次联合议价结果已在陕西省药械集中采购网公布,并将于11月15日起执行。对议价不成功的10种产品和未申报此次联合议价的15种产品,各联

一致性评价政策要放宽?期限要改变?

最近关于一致性评价的时间限制以及政策上都出现了新的呼吁,要求放宽政策和期限。那么,这个要求合理吗?

带量采购结果公布,过一致性评价药品命中率高,重点监控品种暂停交易

带量采购入围结果今天开始公示,过一致性评价药企成最大赢家,一批重点监控药品将暂停交易。

吗丁啉、艾畅 ……25种药被注销批文 这五点是根本原因

截止2018年11月2日,国家药监局公布的已有25个品种的药品被注销注册批准文件,包括维一些老药如生素C注射液,国内曾经十分畅销的多潘立酮混悬液(吗丁啉)和小儿伪麻美芬滴剂(艾畅)等。这些药注册批准文件的注销,或多或少是因为临床使用中发生严重不良反应风险较高,使用风险大于获益,也有桂林兴达药业的7个药品则是因为被依法吊销了药品生产许可证,既就有药物本身的原因,也有生产厂家的原因。那么,国家药监总局

带量采购来了!多地启动

带量采购来了,多地启动!四大变革,重塑行业。

医药代表如何与不同学习风格的医生互动?

昨天是棍棍节,打开手机,或者走到街上,我们应该很明显的知道,我们正处于一个与十年前,甚至五年前完全不同的世界。